Protagenic Therapeutics Statistics
Total Valuation
PTIX has a market cap or net worth of $1.64 million. The enterprise value is -$197,871.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PTIX has 7.53 million shares outstanding. The number of shares has increased by 12.78% in one year.
| Current Share Class | 7.53M |
| Shares Outstanding | 7.53M |
| Shares Change (YoY) | +12.78% |
| Shares Change (QoQ) | +36.70% |
| Owned by Insiders (%) | 18.11% |
| Owned by Institutions (%) | 5.18% |
| Float | 6.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.00
| Current Ratio | 2.00 |
| Quick Ratio | 1.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -236.06% and return on invested capital (ROIC) is -152.23%.
| Return on Equity (ROE) | -236.06% |
| Return on Assets (ROA) | -113.49% |
| Return on Invested Capital (ROIC) | -152.23% |
| Return on Capital Employed (ROCE) | -562.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.84M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.06% in the last 52 weeks. The beta is 0.35, so PTIX's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -87.06% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 42.87 |
| Average Volume (20 Days) | 10,482,532 |
Short Selling Information
The latest short interest is 295,428, so 3.93% of the outstanding shares have been sold short.
| Short Interest | 295,428 |
| Short Previous Month | 70,437 |
| Short % of Shares Out | 3.93% |
| Short % of Float | 4.79% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.70M |
| Pretax Income | n/a |
| Net Income | -5.53M |
| EBITDA | -5.65M |
| EBIT | -5.70M |
| Earnings Per Share (EPS) | -$1.13 |
Full Income StatementBalance Sheet
The company has $1.84 million in cash and n/a in debt, giving a net cash position of $1.84 million or $0.24 per share.
| Cash & Cash Equivalents | 1.84M |
| Total Debt | n/a |
| Net Cash | 1.84M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 1.01M |
| Book Value Per Share | 0.14 |
| Working Capital | 940,108 |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.22M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.22M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |